Cargando…

Do GLP-1–Based Therapies Increase Cancer Risk?

Detalles Bibliográficos
Autores principales:	Nauck, Michael A., Friedrich, Nele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2013
Materias:	Diabetes and Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920789/ https://www.ncbi.nlm.nih.gov/pubmed/23882053 http://dx.doi.org/10.2337/dcS13-2004

Ejemplares similares

Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-Analysis
por: Piccoli, Giovana Fagundes, et al.
Publicado: (2021)

Insulin Therapy and Cancer
por: Home, Philip
Publicado: (2013)

GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond – New Insights 2015
por: Gallwitz, Baptist
Publicado: (2015)

GLP-1 Effects on Islets: Hormonal, Neuronal, or Paracrine?
por: Donath, Marc Y., et al.
Publicado: (2013)

The Role of GIP in the Regulation of GLP-1 Satiety and Nausea
por: Hayes, Matthew R., et al.
Publicado: (2021)

Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes
por: Kaneko, Shizuka
Publicado: (2022)

Epidemiology and Molecular Mechanisms Tying Obesity, Diabetes, and the Metabolic Syndrome With Cancer
por: Gallagher, Emily J., et al.
Publicado: (2013)

Single-Cell Mapping of GLP-1 and GIP Receptor Expression in the Dorsal Vagal Complex
por: Ludwig, Mette Q., et al.
Publicado: (2021)

Study protocol of the randomised placebo-controlled GLOBE trial: GLP-1 for bridging of hyperglycaemia during cardiac surgery
por: Hulst, Abraham H, et al.
Publicado: (2018)

THU264 Enteric Activity Enhanced Ileal GLP-1 Secretion
por: Chen, Yixin, et al.
Publicado: (2023)

RF28 | PSUN182 Risk of Pancreatitis After Glp-1 Receptor Agonist in Individuals With Known History of Pancreatitis
por: Kodali, Alimitha M, et al.
Publicado: (2022)

Incretin-Based Therapies: Viewpoints on the way to consensus
por: Nauck, Michael. A., et al.
Publicado: (2009)

FRI657 Case Series On GLP-1 Receptor Agonist Related Acute Pancreatitis
por: Kumar Kulkarni, Abhigna Uday, et al.
Publicado: (2023)

PSUN192 Therapeutic Benefit of GLP-1 Agonists in Patients with Type 1 Diabetes on Insulin Therapy: an Updated Systematic Review and Meta-analysis
por: Park, Jeayoung, et al.
Publicado: (2022)

GLP-1 receptor agonists as promising disease-modifying agents in WFS1 spectrum disorder
por: Panfili, Eleonora, et al.
Publicado: (2023)

FRI652 Type 2 Diabetes Management: More GLP1 Agonists And Less Metformin?
por: Lopez Maldonado, Francisco J, et al.
Publicado: (2023)

THU334 Trends In GLP-1 Agonist Utilization In Diabetics With And Without Vascular Disease
por: Sargin, Pinar, et al.
Publicado: (2023)

Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?
por: Meier, Juris J., et al.
Publicado: (2010)

MON-646 Novel Use of GLP-1 Receptor Agonist Therapy in MODY-1 (HNF4A Mutation)
por: Broome, David Tyler, et al.
Publicado: (2020)

PSUN270 Magnified Risk of Pancreatitis by GLP-1: A Case of Necrotizing Pancreatitis in a Patient on Dulaglutide with Baseline Elevated Triglycerides
por: Yau, Alice, et al.
Publicado: (2022)

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
por: Pratley, R, et al.
Publicado: (2011)

RF04 | PSUN295 Evolution of Monomeric Multi-Agonists of GLP-1 and NPY Receptors
por: Chichura, Kylie, et al.
Publicado: (2022)

ODP259 Evaluating the Efficacy and Safety of Long-Acting GLP-1 Receptor Agonist in T1DM Patients
por: Mohandas, Deene, et al.
Publicado: (2022)

Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Cardiovascular Risk Management in Patients With Type 2 Diabetes Mellitus: A Systematic Review
por: Parab, Panah, et al.
Publicado: (2023)

Values, preferences and burden of treatment for the initiation of GLP-1 receptor agonists and SGLT-2 inhibitors in adult patients with type 2 diabetes: a systematic review
por: González-González, José Gerardo, et al.
Publicado: (2021)

Characteristics of patients with type 2 diabetes mellitus newly treated with GLP-1 receptor agonists (CHADIG Study): a cross-sectional multicentre study in Spain
por: Conget, Ignacio, et al.
Publicado: (2016)

Management of Late Dumping Syndrome Induced Hypoglycemia With GLP-1R Agonist
por: Shaghouli, Amna Ali, et al.
Publicado: (2021)

ODP171 Choosing GLP-1RA Over Insulin for Patients with Type 2 Diabetes and Severe Hyperglycemia
por: Mamtani, Raashi, et al.
Publicado: (2022)

PSUN134 Loss of Glp-1r Signaling in the β-Cell Impairs Adaptive Proliferation and Insulin Secretion
por: Olvera, Angela, et al.
Publicado: (2022)

PSUN276 GLP1RAs use for treating NALFD in a multidisciplinary clinic in low socioeconomic community
por: West, Brittany, et al.
Publicado: (2022)

THU263 Intestinal Production of H(2)S And Its Regulation Of GLP-2
por: Hammond, Joel, et al.
Publicado: (2023)

MON-130 Optimal Glycemic Control in a Patient with HNF1A MODY with GLP1-RA Monotherapy: Implications for Future Therapy
por: Fantasia, Kathryn, et al.
Publicado: (2019)

GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
por: Nauck, Michael A., et al.
Publicado: (2020)

Ganoderma lucidum polysaccharide (GLP) enhances antitumor immune response by regulating differentiation and inhibition of MDSCs via a CARD9-NF-κB-IDO pathway
por: Wang, Yongyong, et al.
Publicado: (2020)

Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial
por: Larsen, Julie Rask, et al.
Publicado: (2014)

Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis
por: Ma, Hong, et al.
Publicado: (2023)

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
por: Hartman, Mark L., et al.
Publicado: (2020)

MON-666 Glucokinase Within the Hypothalamic Paraventricular Nucleus Is Important in GLP-1 Release
por: Ratnasabapathy, Risheka
Publicado: (2020)

FRI639 Effect Of Early Initiation Of GLP-1 RAs On Weight Reduction Among People With Type 2 Diabetes
por: Chinthammit, Chanadda, et al.
Publicado: (2023)

Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet
por: Jensen, Simon Birk Kjær, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bo2uc3l57p5van0j11f30v6sf0